Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced record revenues for the first quarter of 2024, following a record 2023.
SAN DIEGO--(BUSINESS WIRE)-- Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced record revenues for the first quarter of 2024, following a record 2023. Despite a challenging healthcare environment, revenue in Q1 was ~30% higher than Q1 2023 and ~8% higher than Q4 2023, which was also a record quarter for Kurin.
“We are pleased with Kurin’s continued success and rate of market adoption, and I am grateful for the professionalism and dedication of our team,” said Bob Rogers, CEO of Kurin, Inc. “We continue our expansion of the sales, clinical and manufacturing teams to meet future growth requirements, leaving us well positioned for the changes CMS is forecasting in the blood culture contamination market.”
“We remain the market leader due to our small, simple device, and our continual quest to develop improvements to the Kurin Lock family,” said Rogers. “Hospitals are facing critical financial pressures and Kurin helps those facilities improve their quality of care, and reduce costs at the same time.”
Kurin’s revolutionary approach to the contaminated blood culture problem is based on elegantly simple, intuitive designs that require no additional user steps. Kurin Lock® and Kurin Jet™ both sideline potential contaminants during blood culture collection and provide a better and more sustainable approach than active, conventional mechanical diversion. Contaminated blood cultures are a significant problem, exposing these patients to unnecessary antibiotics, extending hospital stays, and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.
About Kurin, Inc.
Kurin, Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin, manufactured in San Diego, CA, has received FDA 510(k) market clearance. For more information about Kurin, visit the website at www.kurin.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403117350/en/
Matt Heindel
Kurin, Inc.
858-752-9514
mattheindel@kurin.com
Source: Kurin, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20240403117350/en
